The discovery of EGFR-activated mutations as sensitive markers for small-molecule EGFR inhibitors is not only a milestone in the history of lung cancer treatment, but also a model for personalized tumor treatment [102,103,104,105]. The gene discussed is EGFR; the disease is lung carcinoma.